Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

Bang, Y.-J ; Ruiz, E.Yañez ; Van Cutsem, E. ; Lee, K.-W ; Wyrwicz, L. ; Schenker, M. ; Alsina, M. ; Ryu, M.-H ; Chung, H.-C ; Evesque, L. ; Al-Batran, S.-E ; Park, S.H. ; Lichinitser, M. ; Boku, N. ; Moehler, M.H. ; Hong, J. ; Xiong, H. ; Hallwachs, R. ; Conti, I. ; Taieb, J.

Annals of oncology, 2018-10, Vol.29 (10), p.2052-2060 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível